The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2025 | Artificial intelligence in MPNs: current and future applications
In this interview, Andrew Srisuwananukorn, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, discusses the potential of artificial intelligence (AI) in myeloproliferative neoplasms (MPNs), highlighting that AI tools are still in early stages of development in this context and that further research is needed prior to their implementation. Dr Srisuwananukorn mentions his own work, which uses AI for the diagnosis of rare diseases. For example, automated analysis of bone marrow biopsy slides using an AI tool can help to differentiate between pre-fibrotic myelofibrosis and essential thrombocythemia. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So it’s an exciting time to discover artificial intelligence in myeloproliferative neoplasms, but we’re still quite early on. So at this conference at the MPN Workshop of the Carolinas, what I wanted to relay is first a brief primer about what these concepts mean and offer some select use cases about some implementations of artificial intelligence that are closest to practicality...
So it’s an exciting time to discover artificial intelligence in myeloproliferative neoplasms, but we’re still quite early on. So at this conference at the MPN Workshop of the Carolinas, what I wanted to relay is first a brief primer about what these concepts mean and offer some select use cases about some implementations of artificial intelligence that are closest to practicality. But in truth, we’re very, very early on in answering any of these questions and developing these tool sets. So I do think that for the readers out there, you should take a look online and see what other people are looking at. We have researchers in Spain, in London, in the United States, in China that are asking many questions across MPN clinical care, including diagnosis, overall survival across any of the MPNs, particularly myelofibrosis, leukemia-free survival, and many, many more.
So what I’ve shown in my particular research is potentially using AI to diagnose rare diseases, including pre-fibrotic myelofibrosis versus essential thrombocythemia by using an AI tool, looking at bone marrow biopsy slides automatically and making these diagnoses very quickly and accurately. But the truth is there’s so many more opportunities than just diagnosing one versus the other. I’m looking forward to many other implementations, including therapy response, furthering overall survival, or maybe even development of new JAK inhibitors and other novel therapeutics. So much more to come.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Honorarium: Sobi, Incyte; Trials: Incyte, Karyopharm, PharmaEssentia, Telios, Silence.
